Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Bladder Cancer

Free Subscription 22.11.2021 1 Adv Sci (Weinh) 1 Adv Ther 1 Am J Transl Res 1 Am Soc Clin Oncol Educ Book 2 Ann Surg Oncol 3 Anticancer Res 1 BJU Int 1 BMC Cancer 1 BMC Urol 1 BMC Vet Res 1 BMJ Case Rep 1 Br J Cancer 1 Cancer 1 Cancer Cell 2 Cancer Lett 1 Cancer Manag Res 1 Cancer Med 5 Cancers (Basel) 1 Cells 1 Clin Nutr 1 Cureus 2 Diagn Cytopathol 1 Elife 1 Eur Radiol Exp 1 Eur Urol 4 Eur Urol Oncol 2 Evid Based Complement Alternat Med 1 Expert Rev Anticancer Ther 1 Front Immunol 2 Front Oncol 1 Front Pharmacol 1 Future Oncol 2 Indian J Urol 1 Int J Exp Pathol 2 Int J Hyperthermia 1 Int J Mol Sci 1 Int J Radiat Oncol Biol Phys 1 Int J Surg 1 J BUON 5 J Clin Med 1 JCO Glob Oncol 1 Lasers Med Sci 1 Mol Med Rep 1 Mol Nutr Food Res 1 N Z Med J 1 Nucl Med Commun 1 Oncogene 1 Pathol Oncol Res 2 PLoS One 1 Rev Esp Med Nucl Imagen Mol (Engl Ed) 2 Scand J Urol 1 Semin Oncol Nurs 1 Urol Ann

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Sci (Weinh)

1. ZHU J, Tian Z, Li Y, Hua X, et al
   ATG7 Promotes Bladder Cancer Invasion via Autophagy-Mediated Increased ARHGDIB mRNA Stability.
   Adv Sci (Weinh). 2021;8:e2104365.
   PubMed        
   
   

   
   Adv Ther

2. PENG Y, She Z, Peng L, Liu Q, et al
   Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
   Adv Ther. 2021;38:5710-5720.
   PubMed         Abstract available
   
   

   
   Am J Transl Res

3. ZHANG Y, Li Y
   Bladder cancer cells prevent cisplatin-induced oxidative stress by upregulating Nestin1 expression.
   Am J Transl Res. 2021;13:11178-11193.
   PubMed         Abstract available
   
   

   
   Am Soc Clin Oncol Educ Book

4. PARIKH M, Powles T
   Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management.
   Am Soc Clin Oncol Educ Book. 2021;41:e182-e189.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. ZOU L, Liu R, Xu C, Yang C, et al
   Ureteroscopic Cryoablation for Patients with Upper Tract Urothelial Carcinoma of a Solitary Kidney: A Porcine Model and Our Pilot Clinical Experience.
   Ann Surg Oncol. 2021;28:9201-9208.
   PubMed         Abstract available
   
   
6. TEOH JY, Chan EO, Kang SH, Patel MI, et al
   Perioperative Outcomes of Robot-Assisted Radical Cystectomy with Intracorporeal Versus Extracorporeal Urinary Diversion.
   Ann Surg Oncol. 2021;28:9209-9215.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. FISCHER N, Ellinger J, Koeditz B, Heidenreich A, et al
   Predictors for Outcome and Complications Related to Urinary Diversion.
   Anticancer Res. 2021;41:5585-5591.
   PubMed         Abstract available
   
   
8. PALACKA P, Slopovsky J, Obertova J, Chovanec M, et al
   Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
   Anticancer Res. 2021;41:5749-5759.
   PubMed         Abstract available
   
   
9. YUMIOKA T, Honda M, Shimizu R, Teraoka S, et al
   Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
   Anticancer Res. 2021;41:5767-5773.
   PubMed         Abstract available
   
   

   
   BJU Int

10. LEEMING RC, Karagas MR, Zens MS, Schned AR, et al
    Bladder Cancer Risk Variants and Overall and Disease-Specific Survival in Two Independent Cohorts.
    BJU Int. 2021 Nov 14. doi: 10.1111/bju.15640.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. FUKUHARA H, Nohara T, Nishimoto K, Hatakeyama Y, et al
    Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:1223.
    PubMed         Abstract available
    
    

    
    BMC Urol

12. CHOI SY, Lim B, Chi BH, Kim JH, et al
    Hybrid ileal pouch with concomitant anti-refluxing and refluxing ureteroileal anastomosis.
    BMC Urol. 2021;21:92.
    PubMed         Abstract available
    
    

    
    BMC Vet Res

13. KOREC DI, Louke DS, Breitbach JT, Geisler JA, et al
    Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
    BMC Vet Res. 2021;17:320.
    PubMed         Abstract available
    
    

    
    BMJ Case Rep

14. OLIVEIRA AA, Morais J, Ribeiro J, Gouveia PF, et al
    Systemic infection following intravesical therapy with BCG.
    BMJ Case Rep. 2021;14.
    PubMed         Abstract available
    
    

    
    Br J Cancer

15. IKARASHI D, Kitano S, Tsuyukubo T, Takenouchi K, et al
    Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
    Br J Cancer. 2021 Nov 15. pii: 10.1038/s41416-021-01628.
    PubMed         Abstract available
    
    

    
    Cancer

16. HAEUSER L, Marchese M, Schrag D, Trinh QD, et al
    The impact of smoking on radical cystectomy complications increases in elderly patients.
    Cancer. 2021;127:1387-1394.
    PubMed         Abstract available
    
    

    
    Cancer Cell

17. KNOWLES M, Dyrskjot L, Heath EI, Bellmunt J, et al
    Metastatic urothelial carcinoma.
    Cancer Cell. 2021;39:583-585.
    PubMed         Abstract available
    
    

    
    Cancer Lett

18. CAO R, Wang G, Qian K, Chen L, et al
    Corrigendum to "TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARgamma-SIRT1 feedback loop in human bladder cancer cells" [Cancer Lett. 414 (1 February 2018) 278-293].
    Cancer Lett. 2021 Nov 13. pii: S0304-3835(21)00580.
    PubMed        
    
    
19. SANG J, Gan L, Zou MF, Lin ZJ, et al
    Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy.
    Cancer Lett. 2021 Nov 16. pii: S0304-3835(21)00581.
    PubMed         Abstract available
    
    

    
    Cancer Manag Res

20. WANG Z, Yan H, Cheng D, Xu L, et al
    Novel lncRNA LINC01614 Facilitates Bladder Cancer Proliferation, Migration and Invasion Through the miR-217/RUNX2/Wnt/beta-Catenin Axis.
    Cancer Manag Res. 2021;13:8387-8397.
    PubMed         Abstract available
    
    

    
    Cancer Med

21. COOKE IJ, Patil D, Bobrek K, Narayan V, et al
    Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders.
    Cancer Med. 2021 Nov 12. doi: 10.1002/cam4.4346.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

22. FENG C, Wang X, Tao Y, Xie Y, et al
    Single-Cell Proteomic Analysis Dissects the Complexity of Tumor Microenvironment in Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
23. LOPEZ-CORTES R, Vazquez-Estevez S, Fernandez JA, Nunez C, et al
    Proteomics as a Complementary Technique to Characterize Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
24. PELLERIN E, Chabaud S, Pouliot F, Pelletier M, et al
    Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
25. FERRO M, Del Giudice F, Carrieri G, Busetto GM, et al
    The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    
26. LAVALLEE E, Sfakianos JP, Mulholland DJ
    Tumor Heterogeneity and Consequences for Bladder Cancer Treatment.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available
    
    

    
    Cells

27. VON BULOW V, Lichtenberger J, Grevelding CG, Falcone FH, et al
    Does Schistosoma Mansoni Facilitate Carcinogenesis?
    Cells. 2021;10.
    PubMed         Abstract available
    
    

    
    Clin Nutr

28. KE ZB, Chen H, Chen JY, Cai H, et al
    Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Clin Nutr. 2021;40:5792-5801.
    PubMed         Abstract available
    
    

    
    Cureus

29. SELVARAJ N, Dholakia K, Ragavan N
    A Single Tertiary Center Experience in a South Asian Population: Does Tobacco Use Influence Bladder Cancer?
    Cureus. 2021;13:e18734.
    PubMed         Abstract available
    
    

    
    Diagn Cytopathol

30. ROHRA P, Ocampo Gonzalez FA, Yan L, Mir F, et al
    Effect of the Paris system for reporting urinary cytology with histologic follow-up.
    Diagn Cytopathol. 2021;49:691-699.
    PubMed         Abstract available
    
    
31. NARINE N, Rana D, Shelton D, Awad D, et al
    Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology.
    Diagn Cytopathol. 2021 Nov 16. doi: 10.1002/dc.24906.
    PubMed         Abstract available
    
    

    
    Elife

32. HUBER M, Kepesidis KV, Voronina L, Fleischmann F, et al
    Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer.
    Elife. 2021;10.
    PubMed         Abstract available
    
    

    
    Eur Radiol Exp

33. YING T, Borrelli P, Edenbrandt L, Enqvist O, et al
    Automated artificial intelligence-based analysis of skeletal muscle volume predicts overall survival after cystectomy for urinary bladder cancer.
    Eur Radiol Exp. 2021;5:50.
    PubMed         Abstract available
    
    

    
    Eur Urol

34. CLINTON TN
    Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01.
    Eur Urol. 2021;80:323-324.
    PubMed        
    
    

    
    Eur Urol Oncol

35. HERR H
    Improving the Quality of Transurethral Resection of Bladder Tumor: Urologist, Audit Thyself.
    Eur Urol Oncol. 2021;4:20-21.
    PubMed        
    
    
36. MOSTAFID H, Kamat AM, Daneshmand S, Palou J, et al
    Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours.
    Eur Urol Oncol. 2021;4:12-19.
    PubMed         Abstract available
    
    
37. KATES M, Nirschl TR, Baras AS, Sopko NA, et al
    Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
    Eur Urol Oncol. 2021;4:117-120.
    PubMed         Abstract available
    
    
38. MONTORSI F, Bandini M, Moschini M, Deho F, et al
    Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 2021;4:12-9.
    Eur Urol Oncol. 2021;4:126.
    PubMed        
    
    

    
    Evid Based Complement Alternat Med

39. XU H, Dong J, Hou J, Gao R, et al
    Sinomenine Inhibits the Progression of Bladder Cancer Cells by Downregulating LncRNA-HEIH Expression.
    Evid Based Complement Alternat Med. 2021;2021:4699529.
    PubMed         Abstract available
    
    
40. ZHOU S, Fan X, Du X, Liu S, et al
    Effect of Traditional Chinese Medicine Combined with Bladder Perfusion with Hydroxycamptothecin on Color Ultrasound and Clinical Efficacy in Patients with Bladder Cancer Surgery.
    Evid Based Complement Alternat Med. 2021;2021:7178414.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

41. MONTAZERI K, Sonpavde G
    Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
    Expert Rev Anticancer Ther. 2021;21:299-313.
    PubMed         Abstract available
    
    

    
    Front Immunol

42. QIU D, Hu J, Hu J, Yu A, et al
    PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer.
    Front Immunol. 2021;12:705086.
    PubMed         Abstract available
    
    

    
    Front Oncol

43. WANG DQ, Huang Q, Huang X, Jin YH, et al
    Knowledge of and Compliance With Guidelines in the Management of Non-Muscle-Invasive Bladder Cancer: A Survey of Chinese Urologists.
    Front Oncol. 2021;11:735704.
    PubMed         Abstract available
    
    
44. ZHANG H, Wang Y, Ni J, Shi H, et al
    Prognostic Value of Lymphocyte-C-Reactive Protein Ratio in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study.
    Front Oncol. 2021;11:760389.
    PubMed         Abstract available
    
    

    
    Front Pharmacol

45. XIANG Y, Chen X, Wang W, Zhai L, et al
    Natural Product Erianin Inhibits Bladder Cancer Cell Growth by Inducing Ferroptosis via NRF2 Inactivation.
    Front Pharmacol. 2021;12:775506.
    PubMed         Abstract available
    
    

    
    Future Oncol

46. UNSWORTH-WHITE SR, Kitchen MO, Bryan RT
    Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies.
    Future Oncol. 2021 Nov 12:0. doi: 10.2217/fon-2021-0781.
    PubMed         Abstract available
    
    

    
    Indian J Urol

47. NERLI RB, Ghagane SC, Rangrez S, Chandra S, et al
    Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors.
    Indian J Urol. 2021;37:345-349.
    PubMed         Abstract available
    
    
48. KUMAR B
    Pembrolizumab in bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057).
    Indian J Urol. 2021;37:367-368.
    PubMed        
    
    

    
    Int J Exp Pathol

49. FATTAHI S, Karimi M, Ghatreh-Samani M, Taheri F, et al
    Correlation between aryl hydrocarbon receptor and IL-17(+) and Foxp3(+) T-cell infiltration in bladder cancer.
    Int J Exp Pathol. 2021 Nov 11. doi: 10.1111/iep.12392.
    PubMed         Abstract available
    
    

    
    Int J Hyperthermia

50. DOISY L, Cimier A, Adypagavane A, Walz J, et al
    Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy.
    Int J Hyperthermia. 2021;38:1633-1638.
    PubMed         Abstract available
    
    
51. WEN YC, Lee LM, Lin YW, Syu SH, et al
    Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
    Int J Hyperthermia. 2021;38:1627-1632.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

52. WUCHERPFENNIG S, Rose M, Maurer A, Cassataro MA, et al
    Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer.
    Int J Mol Sci. 2021;22.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

53. JOSEPH N
    Optimizing Organ Preservation Strategies in Localized Muscle Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111:1097-1100.
    PubMed        
    
    

    
    Int J Surg

54. ZHOU N, Tian F, Feng Y, Zhao K, et al
    Perioperative outcomes of intracorporeal robot-assisted radical cystectomy versus open radical cystectomy: A systematic review and meta-analysis of comparative studies.
    Int J Surg. 2021;94:106137.
    PubMed         Abstract available
    
    

    
    J BUON

55. TURAL D, Akar E, Baytekin HF, Canoglu D, et al
    Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy.
    J BUON. 2021;26:2117-2125.
    PubMed         Abstract available
    
    

    
    J Clin Med

56. LEMINSKI A, Kaczmarek K, Michalski W, Malkiewicz B, et al
    The Influence of Lymph Node Count on Oncological Outcome of Radical Cystectomy in Chemotherapy Pre-Treated and Chemotherapy-Naive Patients with Muscle Invasive Bladder Cancer.
    J Clin Med. 2021;10.
    PubMed         Abstract available
    
    
57. BASSI P, Di Gianfrancesco L, Salmaso L, Ragonese M, et al
    Improved Non-Invasive Diagnosis of Bladder Cancer with an Electronic Nose: A Large Pilot Study.
    J Clin Med. 2021;10.
    PubMed         Abstract available
    
    
58. PLATA A, Guerrero-Ramos F, Garcia C, Gonzalez-Diaz A, et al
    Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain.
    J Clin Med. 2021;10.
    PubMed         Abstract available
    
    
59. LUTZ CT, Livas L, Presnell SR, Sexton M, et al
    Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity.
    J Clin Med. 2021;10.
    PubMed         Abstract available
    
    
60. SEKINO Y, Pham QT, Kobatake K, Kitano H, et al
    KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer.
    J Clin Med. 2021;10.
    PubMed         Abstract available
    
    

    
    JCO Glob Oncol

61. KORKES F, Timoteo F, Martins S, Nascimento M, et al
    Dramatic Impact of Centralization and a Multidisciplinary Bladder Cancer Program in Reducing Mortality: The CABEM Project.
    JCO Glob Oncol. 2021;7:1547-1555.
    PubMed         Abstract available
    
    

    
    Lasers Med Sci

62. LONG G, Zhang Y, Sun G, Ouyang W, et al
    Safety and efficacy of thulium laser resection of bladder tumors versus transurethral resection of bladder tumors: a systematic review and meta-analysis.
    Lasers Med Sci. 2021;36:1807-1816.
    PubMed         Abstract available
    
    

    
    Mol Med Rep

63. HE J, Qiu Z, Zhang H, Gao Z, et al
    MicroRNA165p/BIMP1/NFkappaB axis regulates autophagy to exert a tumorsuppressive effect on bladder cancer.
    Mol Med Rep. 2021;24.
    PubMed         Abstract available
    
    

    
    Mol Nutr Food Res

64. HUANG L, He C, Zheng S, Wu C, et al
    AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer.
    Mol Nutr Food Res. 2021 Nov 17:e2100738. doi: 10.1002/mnfr.202100738.
    PubMed         Abstract available
    
    

    
    N Z Med J

65. WILD J, Cross A, Davidson P, Frampton C, et al
    Outcomes following open radical cystectomy: an 11-year Christchurch experience.
    N Z Med J. 2021;134:63-73.
    PubMed         Abstract available
    
    

    
    Nucl Med Commun

66. COSKUN N, Cagdas B, Eroglu U, Aslan Y, et al
    The impact of 18F-fluorodeoxyglucose PET/computed tomography on clinical staging in bladder cancer.
    Nucl Med Commun. 2021 Nov 15. pii: 00006231-900000000-97953.
    PubMed         Abstract available
    
    

    
    Oncogene

67. LIU XQ, Shao XR, Liu Y, Dong ZX, et al
    Tight junction protein 1 promotes vasculature remodeling via regulating USP2/TWIST1 in bladder cancer.
    Oncogene. 2021 Nov 15. pii: 10.1038/s41388-021-02112.
    PubMed         Abstract available
    
    

    
    Pathol Oncol Res

68. CAI H, Chen H, Huang Q, Zhu JM, et al
    Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
    Pathol Oncol Res. 2021;27:1609941.
    PubMed         Abstract available
    
    

    
    PLoS One

69. ZLOWOCKA-PERLOWSKA E, Debniak T, Slojewski M, van de Wetering T, et al
    Survival of bladder or renal cancer in patients with CHEK2 mutations.
    PLoS One. 2021;16:e0257132.
    PubMed         Abstract available
    
    
70. CHANG YH, Tam HL, Lu MC, Huang HS, et al
    Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.
    PLoS One. 2021;16:e0254011.
    PubMed         Abstract available
    
    

    
    Rev Esp Med Nucl Imagen Mol (Engl Ed)

71. LOPEZ-MORA DA, Fernandez A, Duch J, Carrio I, et al
    Follow-up (18)F-FDG PET/CT in an oncological asymptomatic COVID-19 patient.
    Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021;40:374-375.
    PubMed        
    
    

    
    Scand J Urol

72. RUSSELL B, Liedberg F, Hagberg O, Ullen A, et al
    Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer.
    Scand J Urol. 2021 Nov 13:1-7. doi: 10.1080/21681805.2021.2002399.
    PubMed         Abstract available
    
    
73. KORNER SK, Jensen JB
    A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019.
    Scand J Urol. 2021 Nov 13:1-5. doi: 10.1080/21681805.2021.2002400.
    PubMed         Abstract available
    
    

    
    Semin Oncol Nurs

74. RAMMANT E, Fonteyne V, Van Goethem V, Verhaeghe S, et al
    Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patients' Perspectives.
    Semin Oncol Nurs. 2021 Nov 7:151226. doi: 10.1016/j.soncn.2021.151226.
    PubMed         Abstract available
    
    

    
    Urol Ann

75. THYAVIHALLY YB, Waigankar SS, Dev P, Asari A, et al
    Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk n
    Urol Ann. 2021;13:424-430.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: